The Comparability of Etanercept Pharmacokinetics in Healthy Japanese and American Subjects
Authors:
- Hisayuki SekinoHSHisayuki Sekino
- Noriaki YamashitaNYNoriaki Yamashita
- Shinichi TsuchiwataSTShinichi Tsuchiwata
- Hanjui LiuHLHanjui Liu
- Joan M. Korth‐BradleyJKJoan M. Korth‐Bradley
- 1 April 2006
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 46 (4) , 418-423
Abstract
Thirty Japanese (J) and 32 American (A) healthy subjects received single doses of etanercept by subcutaneous injection, in 3 separate trials. Serum samples were collected for 480 hours after dosing. Concentrations were determined using enzyme‐linked immunosorbent assay methods. Pharmacokinetic parameters were calculated using both noncompartmental and compartmental methods. Etanercept was slowly absorbed, with mean ± SD time to maximum serum concentration of 47 ± 15 hours (J), and 51 ± 20 hours (A). The maximum serum concentration and area under the concentration time curve increased for doses 10 mg, 25 mg, and 50 mg, in a linear relationship. Etanercept was slowly eliminated, with observed mean ± SD half‐life of 80 ± 25 hours (J) and 75 ± 15 hours (A) and mean ± SD apparent clearance of 144 ± 65 mL/h (J) and 132 ± 74 mL/h (A). Very low concentrations of etanercept were observed in the urine samples collected in the Japanese subjects. All adverse reactions observed resolved without issue, and none required discontinuation from the study.Keywords
This publication has 10 references indexed in Scilit:
- Clinical Pharmacokinetics of Etanercept: A Fully Humanized Soluble Recombinant Tumor Necrosis Factor Receptor Fusion ProteinThe Journal of Clinical Pharmacology, 2005
- Population Pharmacokinetic Analysis and Simulation of the Time‐Concentration Profile of Etanercept in Pediatric Patients With Juvenile Rheumatoid ArthritisThe Journal of Clinical Pharmacology, 2005
- Absence of a Clinically Relevant Interaction Between Etanercept and DigoxinThe Journal of Clinical Pharmacology, 2004
- Unaltered Etanercept Pharmacokinetics With Concurrent Methotrexate in Patients With Rheumatoid ArthritisThe Journal of Clinical Pharmacology, 2004
- Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritisInt. Journal of Clinical Pharmacology and Therapeutics, 2004
- Pharmacokinetics of etanercept, a TNF antagonist, in patients with psoriasis treated in two double-blind phase 3 trialsJournal of the American Academy of Dermatology, 2004
- EtanerceptDrugs, 2002
- The pharmacokinetics of etanercept in patients with heart failureBritish Journal of Clinical Pharmacology, 2001
- The Pharmacokinetics of Etanercept in Healthy VolunteersAnnals of Pharmacotherapy, 2000
- Issues of Special Populations in Drug DevelopmentDrug Information Journal, 1993